Ovid Therapeutics - OVID Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $4.04
  • Forecasted Upside: 243.83%
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 4 Buy Ratings
  • 1 Strong Buy Ratings
$1.18
▼ -0.015 (-1.26%)

This chart shows the closing price for OVID by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Ovid Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OVID and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OVID

Analyst Price Target is $4.04
▲ +243.83% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Ovid Therapeutics in the last 3 months. The average price target is $4.04, with a high forecast of $8.00 and a low forecast of $1.20. The average price target represents a 243.83% upside from the last price of $1.18.

This chart shows the closing price for OVID for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 7 polled investment analysts is to moderate buy stock in Ovid Therapeutics. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 1 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
5/9/2023
  • 1 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
8/7/2023
  • 1 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
11/5/2023
  • 1 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
2/3/2024
  • 1 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
5/3/2024
  • 1 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
8/1/2024
  • 1 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/30/2024
  • 1 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/30/2024

Latest Recommendations

  • 1 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/30/2024HC WainwrightReiterated RatingBuy ➝ Buy$3.00 ➝ $3.00
8/30/2024William BlairUpgradeStrong-Buy
8/19/2024HC WainwrightReiterated RatingBuy ➝ Buy$3.00 ➝ $3.00
7/26/2024HC WainwrightReiterated RatingBuy ➝ Buy$3.00 ➝ $3.00
7/2/2024HC WainwrightReiterated RatingBuy ➝ Buy$3.00 ➝ $3.00
6/18/2024BTIG ResearchLower TargetBuy ➝ Buy$11.00 ➝ $5.00
6/18/2024B. RileyLower TargetBuy ➝ Buy$9.00 ➝ $3.00
6/18/2024CitigroupLower TargetNeutral ➝ Neutral$3.50 ➝ $1.20
6/18/2024HC WainwrightLower TargetBuy ➝ Buy$9.00 ➝ $3.00
6/18/2024OppenheimerDowngradeOutperform ➝ Market Perform
5/16/2024HC WainwrightReiterated RatingBuy ➝ Buy$9.00
5/7/2024CitigroupLower TargetNeutral ➝ Neutral$4.00 ➝ $3.50
4/30/2024B. RileyInitiated CoverageBuy$9.00
4/29/2024HC WainwrightInitiated CoverageBuy$9.00
4/5/2024WedbushInitiated CoverageOutperform$8.00
12/21/2023BTIG ResearchInitiated CoverageBuy$11.00
10/13/2023OppenheimerInitiated CoverageOutperform$8.00
3/16/2023CitigroupBoost Target$2.00 ➝ $2.50
8/29/2022CitigroupBoost TargetNeutral$2.40 ➝ $2.50
5/20/2022CitigroupLower TargetNeutral$2.40
8/30/2021JMP SecuritiesReiterated RatingHold
8/25/2021CitigroupLower TargetNeutral$4.50 ➝ $4.00
4/26/2021Cantor FitzgeraldReiterated RatingOverweight ➝ Neutral$8.00 ➝ $4.00
4/20/2021Cantor FitzgeraldDowngradeOverweight ➝ Neutral$8.00 ➝ $4.00
3/4/2021UBS GroupBoost TargetNeutral$4.00 ➝ $5.00
3/3/2021Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$5.00
12/2/2020Cantor FitzgeraldReiterated RatingOverweight
12/2/2020Royal Bank of CanadaLower TargetOutperform$17.00 ➝ $5.00
12/2/2020Smith Barney CitigroupDowngradeBuy ➝ Neutral$10.00 ➝ $40.00
12/2/2020LADENBURG THALM/SH SHLower TargetBuy$21.00 ➝ $7.00
12/2/2020JMP SecuritiesDowngradeOutperform ➝ Market Perform
11/19/2020Royal Bank of CanadaReiterated RatingBuy$17.00
10/2/2020William BlairReiterated RatingBuy
8/26/2020Cantor FitzgeraldLower Target$13.00 ➝ $12.00
8/26/2020Royal Bank of CanadaBoost TargetOutperform$13.00 ➝ $17.00
8/26/2020CitigroupBoost TargetIn-Line ➝ Buy$9.00 ➝ $10.00
8/11/2020William BlairReiterated RatingBuy
7/26/2020Royal Bank of CanadaReiterated RatingBuy$13.00
7/17/2020William BlairReiterated RatingBuy
7/14/2020CitigroupBoost TargetBuy$8.00 ➝ $9.00
7/13/2020LADENBURG THALM/SH SHReiterated RatingBuy$21.00
6/21/2020Royal Bank of CanadaReiterated RatingBuy$13.00
6/18/2020Piper SandlerReiterated RatingOverweight$10.00
6/18/2020LADENBURG THALM/SH SHReiterated RatingBuy$20.00
6/18/2020Cantor FitzgeraldBoost TargetOverweight$7.00 ➝ $13.00
3/11/2020William BlairReiterated RatingOutperform
3/6/2020LADENBURG THALM/SH SHReiterated RatingBuy$20.00
11/22/2019William BlairReiterated RatingBuy
11/11/2019CowenReiterated RatingBuy
(Data available from 10/30/2019 forward)

News Sentiment Rating

0.96 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
4/3/2024
  • 4 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/3/2024
  • 5 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
6/2/2024
  • 2 very positive mentions
  • 6 positive mentions
  • 5 negative mentions
  • 0 very negative mentions
7/2/2024
  • 3 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/1/2024
  • 5 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/31/2024
  • 1 very positive mentions
  • 15 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/30/2024
  • 5 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/30/2024

Current Sentiment

  • 5 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Ovid Therapeutics logo
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
Read More

Today's Range

Now: $1.18
Low: $1.16
High: $1.21

50 Day Range

MA: $1.15
Low: $1.02
High: $1.30

52 Week Range

Now: $1.18
Low: $0.68
High: $4.10

Volume

57,197 shs

Average Volume

396,526 shs

Market Capitalization

$83.39 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.39

Frequently Asked Questions

What sell-side analysts currently cover shares of Ovid Therapeutics?

The following sell-side analysts have issued reports on Ovid Therapeutics in the last twelve months: B. Riley, BTIG Research, Citigroup Inc., HC Wainwright, Oppenheimer Holdings Inc., Wedbush, and William Blair.
View the latest analyst ratings for OVID.

What is the current price target for Ovid Therapeutics?

5 Wall Street analysts have set twelve-month price targets for Ovid Therapeutics in the last year. Their average twelve-month price target is $4.04, suggesting a possible upside of 243.8%. Wedbush has the highest price target set, predicting OVID will reach $8.00 in the next twelve months. Citigroup Inc. has the lowest price target set, forecasting a price of $1.20 for Ovid Therapeutics in the next year.
View the latest price targets for OVID.

What is the current consensus analyst rating for Ovid Therapeutics?

Ovid Therapeutics currently has 2 hold ratings, 4 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for OVID.

What other companies compete with Ovid Therapeutics?

How do I contact Ovid Therapeutics' investor relations team?

Ovid Therapeutics' physical mailing address is 1460 Broadway Suite 15044, New York NY, 10036. The company's listed phone number is (646) 661-7661 and its investor relations email address is [email protected]. The official website for Ovid Therapeutics is www.ovidrx.com. Learn More about contacing Ovid Therapeutics investor relations.